Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex pilot study for resistant spasticity in chronic spinal cord injury
2022-001777-31Phase 4Completed
- Sponsor
- Institut Guttmann
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cannabidiol in Muscle spasm and spinal cord injury (SCI), sponsored by Institut Guttmann. Started Jan 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
Muscle spasmspinal cord injury (SCI)
Beyond the preview
Go deeper on 2022-001777-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001777-31.